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Cost-effectiveness is arguably the most 
influential factor in the provision of 
healthcare in the 21st century. Health 
technology assessments (HTAs), 
performed by organisations such as the 
National Institute for Health and Clinical 
Excellence (NICE) and the Scottish 
Medicines Consortium (SMC), can make or 
break a drug – and, consequently, make or 
break the lives of many people who may 
benefit from those drugs. 
Cost-effectiveness analysis (CEA) is one of 
the techniques used in economic 
evaluation to compare the costs and health 
benefits of an intervention (e.g. a structured 
education programme or a new treatment). 
The objective is to see whether or not it is 
worth spending money on this intervention, 
i.e. to maximise health benefits within a 
resource-limited health service. 
NICE appraisals are based primarily on a 
type of CEA called cost-utility analysis, 
where the benefits are expressed in terms 
of the quality and quantity of life delivered 
by a given treatment, i.e. quality-adjusted 
life years (QALYs). NICE has adopted a 
cost effectiveness threshold range of 
£20,000-£30,000 per QALY gained, 
although this figure has no basis in either 
theory or evidence and could be argued to 
be too low when one considers the wider 
personal and social costs of incapacity.  
Cost-effectiveness is only one of a number 
of criteria that need to be considered when 
rationing healthcare; others include issues 
of equity, needs and priorities. Although 
NICE does not accept or reject therapies 
based on cost-effectiveness alone, it is 
undoubtedly a major deciding factor. There 
are two main problems with this system: 
(1) it accounts only for costs to the NHS  
(2) it does not consider the patients’ 
perspective in decision-making 
Pfizer’s inhaled insulin Exubera® was 
potentially one of the biggest 
breakthroughs for people with diabetes 
since insulin was first discovered by 
Banting and Best in 1922. Unfortunately, 
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insulin without the need for injection was 
more expensive and (apparently) no more 
effective than injected short-acting insulin, 
so NICE decided that it “was not an 
effective use of National Health Service 
(NHS) resources”. 
Another case in point is in macular 
degeneration (MD), where the cells of the 
macula become damaged and stop 
working, resulting in central vision 
blindness. Most commonly, one eye is 
affected at a time. In June 2007, NICE 
assessed two potential drugs for wet age-
related MD. They dismissed the use of one 
and recommended that the other is 
prescribed only when both eyes have been 
affected, with the treatment being given 
only for the least degenerated eye. This 
suggests that people with MD must lose 
total sight in one eye before being offered 
treatment, despite evidence to suggest that 
it is actually more expensive for society (if 
not the NHS) to support someone once 
they have lost their sight than to provide 
this treatment1. 
Whatever you may think of NICE, it has 
brought the process of healthcare rationing 
out into the open. Someone (or some 
organisation) needs to decide what 
treatments can be afforded and for whom. 
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 “Do we really 
only value the 
things we can 
count? 
Or should we be 
counting the 
things that we 
value?” 
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For many years, that process has gone 
largely unchecked behind closed doors, 
with decisions made on a case-by-case 
basis in a “postcode lottery”. At least NICE 
has made an attempt to ensure that such 
decisions are transparent, independent and 
evidence-based. 
So, in a resource-limited environment, 
someone is required to place a value on 
health. The problem comes in defining 
“health” and deciding whether other factors 
such as quality of life (QoL) and treatment 
satisfaction can and should be part of the 
CEA equation. 
In the cases of Exubera® and MD (above), 
neither treatment necessarily improves 
health (or certainly not in the way it is 
measured in HTAs), but they can improve 
QoL and other patient-reported outcomes 
(PROs). PROs refer to a variety of 
outcomes that can be provided only by the 
patient2. Examples of these include 
symptom severity and bothersomeness, 
perception of daily functioning, feelings of 
well-being, satisfaction with treatment, and 
health-related QoL. NICE’s principal choice 
of generic health status questionnaires are 
unsuitable for measuring the quality of 
someone’s life (a complex construct distinct 
from health status) and ignore a host of 
other outcomes of importance to the 
individual patient.  
The EuroQoL 5-Dimension questionnaire 
(EQ-5D)3 is most frequently used to provide 
data on QALYs, as it is weighted according 
to the social preferences of the UK 
population. However, this generic measure 
evaluates only five dimensions of health 
status including mobility, self-care, usual 
activities, pain / discomfort, and anxiety / 
depression. It does not measure the quality 
of someone’s life in a way that is sensitive 
to a variety of conditions or allows the 
individual to indicate what is important for 
them personally and how that is impacted 
by their illness. Conditions like MD, 
diabetes and breast cancer, do not 
necessarily result in major incapacity (as 
measured by the EQ-5D) but the 
impairments that are not measured can be 
substantial. To paraphrase Albert Einstein: 
do we really only value the things we can 
count? Or should we be counting the things 
that we value? Other PROs have been 
acknowledged as important to drug 
regulators2,4, but are not currently 
considered by NICE in making decisions 
on cost-effectiveness, despite clear 
pathways from treatment to cost which 
incorporate such factors. 
In an attempt to speed up the drug 
approval process, the government has 
recently outlined plans which dictate that 
NHS trusts will no longer be able to refuse 
drugs on the basis of cost alone. With 
much recent controversy over the 
availability of certain life-saving cancer 
drugs, this could be interpreted as long 
over due, but it may also seem highly 
inappropriate in a resource-limited NHS. 
However, it is also clear that the current 
system of evaluating QALYs in isolation is 
unsuitable. To maximise the health benefits 
of treatments available on the NHS, the 
impact of a condition on the individual must 
be considered, as it is apparent that this 
directly affects the impact and cost of the 
disease on the wider population. 
Interestingly, while health psychologists 
have been involved in National Service 
Frameworks in recent years, there remain 
none on the board at NICE. What does that 
say about the values of NICE? We wouldn’t 
like to comment! 
